Current status of accelerated corneal cross-linking

Area of Science:

• Ophthalmology
• Corneal Surgery
• Biomedical Engineering

Background:

• Corneal cross-linking (CXL) with riboflavin strengthens the cornea.
• It is used to treat progressive corneal ectasia, including keratoconus and post-LASIK ectasia.
• Shorter treatment times are desired for patient convenience and increased surgical capacity.

Purpose of the Study:

• To discuss the principles and techniques of accelerated corneal cross-linking.
• To address the growing interest in reducing CXL treatment duration.
• To facilitate patient flow, particularly when CXL is combined with laser vision correction procedures.

Main Methods:

• Review of existing literature on accelerated corneal cross-linking protocols.
• Discussion of modifications to standard CXL procedures to reduce time.
• Analysis of factors influencing treatment acceleration.

Main Results:

• Accelerated CXL techniques aim to achieve similar biomechanical results in less time.
• Various methods are being explored to shorten the duration of riboflavin application and UV-A irradiation.
• Successful acceleration can improve patient throughput in ophthalmic clinics.

Conclusions:

• Accelerated corneal cross-linking offers a promising alternative for efficient ectasia treatment.
• Further research and standardization are needed to optimize accelerated CXL protocols.
• This approach holds potential for broader adoption in managing corneal ectatic disorders.